07:40 AM EDT, 07/16/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) agreed to acquire US-listed rapid-acting neuroplastogens developer AtaiBeckley for an upfront cash consideration of $6.75 per share. The deal represents an equity value of $2.8 billion and includes an additional potential consideration of $2.50 per share, or $1 billion, in the form of a contingent value right, the pharmaceutical giant said Thursday. Subject to approval by AtaiBeckley's shareholders and regulatory clearances, the deal is expected to close in the third quarter.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.